KMT2A and acute myeloid leukemia: These findings indicate that co-treatment with SNDX-50469 or SNDX-5613 and OTX015 or GNE-781 are effective combination therapies worthy of further in vivo testing and development in AML with MLL1-r and mtNPM1.